Cardiogeni PLC – Director’s Dealings
RNS Number : 7920Y
Cardiogeni PLC
28 February 2025
28 February 2025
Cardiogeni PLC
(“Cardiogeni” or the “Company”)
Director’s Dealings
Cardiogeni (AQSE: CGNI), a UK clinical stage biotechnology company founded by 2007 Nobel Laureate Sir Martin Evans to advance novel heart failure medicines through human trials, announces that Darrin Disley, Executive Chairman of Cardiogeni has purchased a total of 152,205 ordinary shares of the Company, the details of which are set out in the notification below.
Following the purchase, Darrin Disley will hold 2,816,017 ordinary shares representing 3.30% of Cardiogeni’s issued share capital.
The directors of Cardiogeni accept responsibility for this announcement.
This announcement, including the notification below, is made in accordance with the requirements of the UK Market Abuse Regulation.
For further information please contact:
| Cardiogeni PLC | |
| Dr Darrin M Disley OBE, Executive Chairman | Via First Sentinel |
| First Sentinel Corporate Finance LimitedCorporate Adviser | |
| Brian StockbridgeGabrielle Cordeiro | +44 (0) 7858 888007 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Darrin Disley |
| 2. | Reason for the Notification | |
| a) | Position/status | Executive Chairman |
| b) | Initial notification / Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Cardiogeni PLC |
| b) | LEI | 9845000F8F59ATZD8F92 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Ordinary shares |
| ISIN | GB00BTBLFC12 | |
| b) | Nature of the transaction | Purchase of shares |
| c) | Price(s) and volume(s) | DatePrice(s)Volume(s) 1. 25-02-2025£0.1550,0002. 26-02-2025£0.2260,0003. 27-02-2025£0.22£0.2240,0002,205 |
| d) | Aggregated information: · Aggregated volume · Price | Aggregated volume: 152,205Price: £0.197 |
| e) | Date of the transaction | 25/02/2025 to 27/02/2025 |
| f) | Place of the Transaction | Aquis Exchange Growth Market (AQSE) |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom
Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDNEXSEMFAWEISEDE]]>